And thus dexamethasone and H1 and H2 -receptor antagonists should be used as premedication to avoid hypersensitivity reactions.[6] Nanoparticle albumin-bound paclitaxel (nab-paclitaxel [nab-PTX]), a solvent free nanometersized form of paclitaxel, was initially invented in 1992 to avoid the toxicities associated with castor oil as it can be administered with shorter fusion schedule (30 minutes) and no premedication[7,8] and it has been administrated to treat breast cancer by FDA since 2005. This evidence concerns the gene ALB and breast carcinoma.